Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 54,972 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: XmAb5574; Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 3
States / cities: Augusta, Georgia • Columbus, Ohio • Nashville, Tennessee

Conditions: Chronic Obstructive Pulmonary Disease, Asthma, Pulmonary Embolism, Pneumonia, Congestive Heart Failure
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chronic Spontaneous Urticaria
Interventions: LOU064 25 mg (b.i.d), Placebo, LOU064 25 mg (b.i.d) as a tablet.; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 26
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • Bakersfield, California + 23 more

Conditions: Rheumatic Diseases
Interventions: Cortisol; Drug
Lead sponsor: Helen Foundation; Other
Eligibility: 18 Years and older
Enrollment: 2,430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2016
U.S. locations: 1
States / cities: Apache Junction, Arizona

Conditions: Multiple Myeloma
Interventions: filgrastim, melphalan, Stem Cell Infusion; Biological · Drug · Procedure
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: Provider Education, Hypertension Alert, Patient Education; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 21 Years to 90 Years
Enrollment: 1,300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Stroke
Interventions: Dexedrine, Active tDCS, Speech Therapy, Placebo, Sham tDCS; Drug · Device · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Heart Failure
Interventions: Echocardiogram/SonR; Other
Lead sponsor: Piedmont Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Herpes Simplex
Interventions: acyclovir sodium; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Artificial Intelligence (AI), Clinical Reasoning
Interventions: Articulate Medical Intelligence Explorer (AMIE); Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Solid Tumor
Interventions: SRF617, Gemcitabine, Albumin-Bound Paclitaxel, Pembrolizumab; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: Duarte, California • Los Angeles, California • Aurora, Colorado + 5 more

Conditions: Prostate Cancer
Interventions: Multiparametric MRI; Device
Lead sponsor: Henry Ford Health System; Other
Eligibility: Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: End Stage Renal Disease, Chronic Kidney Diseases
Interventions: Ferric Citrate; Drug
Lead sponsor: Sreedhar Mandayam; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Schizophrenia
Interventions: Placebo, Risperdal; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions: carboplatin, gemcitabine, paclitaxel, surgery; Drug · Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 128
States / cities: Anchorage, Alaska • Glendale, Arizona • Mesa, Arizona + 89 more

Conditions: Sarcoma
Interventions: trabectedin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York

Conditions: Persistent Cough in IPF, Chronic Cough, IPF
Interventions: RVT-1601, Placebo; Drug
Lead sponsor: Respivant Sciences GmbH; Industry
Eligibility: 40 Years to 89 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 28
States / cities: Birmingham, Alabama • Sacramento, California • San Francisco, California + 25 more

Conditions: Renal Cell Carcinoma
Interventions: 150-Water, 62Cu-ethylglyoxal bis, Positron Emission Tomography, Sunitinib; Drug · Procedure
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Recurrent Platinum Resistant Ovarian Cancer
Interventions: cediranib and olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 25
States / cities: Mobile, Alabama • Anchorage, Alaska • Downey, California + 21 more

Conditions: Borderline Personality Disorder
Interventions: 40 IU Intranasal Oxytocin, Placebo, 24 IU intranasal Oxytocin; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypercholesterolemia
Interventions: Bempedoic acid 180mg, Ezetimibe 10mg, Atorvastatin 20mg, Placebo; Drug · Other
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 11
States / cities: Champaign, Illinois • Cary, North Carolina • Charlotte, North Carolina + 7 more

Conditions: Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
Interventions: docetaxel, placebo, gefitinib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis
Interventions: noninvasive positive pressure ventilation; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: CD55-deficient Protein-losing Enteropathy, CHAPLE
Interventions: Pozelimab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 1 Year and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia

Evaluation of ST2 and IL-33 in Patients Presenting to the Emergency Department With Trouble Breathing

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines

Patient Self-administration of Cortisol for Cortisol-responding Disorders in Men and Women Over the Age of 17

HD Melphalan and SCT in Patients With IGDD or LCDD

Improving Practice Patterns for the Treatment of Hypertension

Dextroamphetamine and tDCS to Improve the Fluency

Atrio-Ventricular (AV) Delay Optimization Using Echocardiography Versus the SonR Signal

Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia

AMIE's Clinical Conversational Abilities in an Urgent Care Setting

Study of SRF617 in Patients With Advanced Solid Tumors

Multi-parametric Magnetic Resonance Imaging for Prostate Cancer Patients

Ferric Citrate in ESRD Pilot Project

Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine

S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium

Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma

A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF

PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma

Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer

The Effect of Oxytocin Administration on Interpersonal Cooperation in Borderline Personality Disorder Patients and Healthy Adults

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer

Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement

Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)